Drug Detail

Information about BMS-754807

Generic Name
IND	BMS-754807
Brand Name (US)
Manufacturer	Bristol-Myers Squibb
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 1
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	IGF1R inhibitor

An orally bioavailable antagonist of human insulin-like growth factor type I receptor (IGF-1R) with potential antitumor activity. IGF-1R inhibits IGF-1R-mediated signaling pathways; inhibition of IGF-1R-mediated signaling pathways may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival.
IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs.
Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.